

### **REMARKS**

The Examiner has issued a restriction requirement stating that the application claims two separate inventions. Specifically, the Examiner identifies the two inventions as being:

- I. Claims 1-58, drawn to a method for treating a patient having a disease associated with over-expression of EZH2 comprising administering to the patient a therapeutically effective amount of DNA methylation inhibitor; and
- II. Claims 59-105, drawn to a method for treating a patient having a disease associated with over-expression of EZH2 comprising administering to the patient a therapeutically effective amount of a histone deacetylase inhibitor.

Applicant elects Group I (Claims 1-58) without traverse. Accordingly, claims 59-105 are canceled without prejudice.

Applicant reserves the right pursuant to 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected inventions during the pendency of the present application.

**CONCLUSION**

In light of the amendments and arguments set forth above, Applicants earnestly believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent to issuance. Should the Examiner have any questions, Examiner is encouraged to telephone the undersigned.

The Commissioner is authorized to charge any additional fees which may be required, including petition fees and extension of time fees, to Deposit Account No. 23-2415 (Docket No. 12636-305).

Respectfully,  
WILSON SONSINI GOODRICH & ROSATI

Date: October 24, 2006

By:



Shirley Chen, Ph.D, Esq.  
Reg. No. 44,608

650 Page Mill Road  
Palo Alto, CA 94304-1505  
Direct dial: (650) 565-3856  
Customer No. 021971